Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2007

Caliper to Explore Novel Indications for Drug Candidates at Pfizer

  • Caliper's Discovery Alliances & Services division will conduct certain in vivo profiling experiments for Pfizer. These will enable Pfizer to explore new indications for some compounds in its R&D pipeline.

    Under the one-year contract, Caliper will utilize its in vivo compound profiling platform to study the effects of acute or chronic drug dosing in mice to try and uncover new uses for compounds already in development.

    "On average, a drug has six and a half to seven years of patent life remaining after being launched," says Kevin Hrusovsky, president and CEO of Caliper Life Sciences. "Our portfolio of advanced in vitro and in vivo capabilities is being leveraged by pharmaceutical companies to explore the potential for drugs to treat indications beyond their original design."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »